title: Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18.
abstract: Prophylactic vaccination against HPV 16 and 18 has the potential for effective prevention of high-grade precancer (cervical intraepithelial neoplasia [CIN)] 2/3) and ICC caused by these viruses (globally 50 and 70%, respectively) when employed in women prior to starting sexual activity. To provide data for decisions on HPV vaccination in China, we determined HPV type-distribution in ICC and CIN 2/3 from women of different regions within China. A multicenter study was conducted by randomized sampling of paraffin blocks of 664 ICC (630 squamous cell carcinoma [SCC]; 34 adenocarcinoma [ADC]), 569 CIN 2/3 cases from seven regions of China. Histological diagnosis was confirmed in 1,233 cases by consensus review. HPV DNA was detected using the SPF10 LiPA25 version 1 assay. HPV prevalence was 97.6% in SCC, 85.3% in adenocarcinoma, and 98.9% in CIN 2/3. HPV 16 (76.7%) and HPV 18 (7.8%) were the most common, together accounting for 84.5% of SCC, followed by HPV 31 (3.2%), HPV 52 (2.2%), and HPV 58 (2.2%). HPV positivity in SCC did not differ notably by region. However, SCC cases from women <or=34 years had higher HPV 16 positivity than women over 50 years, among whom HPV 52, 58, and 39 were more common. HPV 16 and 18 were under-represented, whereas HPV 31, 52, and 58 were over-represented in CIN2/3 compared to SCC. The potential impact of vaccines against oncogenic HPV types 16 and 18 is estimated to be high (84.5%) against total SCC. These data are critical for China's future evaluation of the cost-effectiveness of current cervical cancer vaccines and of HPV-based screening guidelines.
authors.affiliation: Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
authors.forename: Wen
authors.initials: W
authors.lastname: Chen
authors.forename: Xun
authors.initials: X
authors.lastname: Zhang
authors.forename: Anco
authors.initials: A
authors.lastname: Molijn
authors.forename: David
authors.initials: D
authors.lastname: Jenkins
authors.forename: Ju-Fang
authors.initials: JF
authors.lastname: Shi
authors.forename: Wim
authors.initials: W
authors.lastname: Quint
authors.forename: Johannes E
authors.initials: JE
authors.lastname: Schmidt
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Yu-Ling
authors.initials: YL
authors.lastname: Liu
authors.forename: Lian-Kun
authors.initials: LK
authors.lastname: Li
authors.forename: Hong
authors.initials: H
authors.lastname: Shi
authors.forename: Ji-Hong
authors.initials: JH
authors.lastname: Liu
authors.forename: Xing
authors.initials: X
authors.lastname: Xie
authors.forename: Mayinuer
authors.initials: M
authors.lastname: Niyazi
authors.forename: Pei
authors.initials: P
authors.lastname: Yang
authors.forename: Li-Hui
authors.initials: LH
authors.lastname: Wei
authors.forename: Long-Yu
authors.initials: LY
authors.lastname: Li
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Jin-Feng
authors.initials: JF
authors.lastname: Liu
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhou
authors.forename: Ying
authors.initials: Y
authors.lastname: Hong
authors.forename: Li
authors.initials: L
authors.lastname: Li
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
authors.forename: Hong-Lin
authors.initials: HL
authors.lastname: Zhou
authors.forename: Mei-Lu
authors.initials: ML
authors.lastname: Bian
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: You-Lin
authors.initials: YL
authors.lastname: Qiao
authors.forename: Jennifer S
authors.initials: JS
authors.lastname: Smith
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology / Q000473:pathology / Q000821:virology*; D002681:China; D005260:Female; D052162:Human papillomavirus 16 / Q000302:isolation & purification; D052161:Human papillomavirus 18 / Q000302:isolation & purification; D006801:Humans; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000821:virology*; D016133:Polymerase Chain Reaction; D015995:Prevalence; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000821:virology*; D055815:Young Adult; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000473:pathology / Q000821:virology*